TFF Pharmaceuticals (TFFP) announced that the government will be advancing several next-generation medical countermeasures formulated with its Thin Film Freezing technology into advanced preclinical testing. TFF Pharmaceuticals is collaborating with Leidos (LDOS), a leading Fortune 500 information technology, engineering and science solutions and services leader, to develop next-generation MCMs designed to protect military and healthcare personnel against future chemical and biological threats. The research is funded by the Defense Advanced Research Projects Agency under a contract through the Personalized Protective Biosystems program. The candidate MCMs delivered by Leidos to TFF Pharmaceuticals have been successfully formulated utilizing the Company’s proprietary Thin Film Freezing technology platform. Formulated materials have demonstrated neutralizing activity in well-validated in vitro models. The MCMs are now progressing into in vivo preclinical testing, which will be conducted at DARPA-contracted laboratories.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF, Cleveland Clinic to advance multivalent universal influenza vaccines
- TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
- TFF Pharmaceuticals provides update on TFF TAC Phase 2 trial
- TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
- TFF Pharmaceuticals 1.67M share Secondary priced at $2.88